
PostEra: ML-driven drug discovery, advancing medicinal chemistry with top biopharma partnerships.
PostEra, founded with the mission to revolutionize medicinal chemistry through machine learning, aims to accelerate drug discovery and bring more cures to patients. The company leverages advanced AI technologies to streamline the Design-Make-Test cycle in medicinal chemistry. PostEra offers services that include advancing small molecule programs through partnerships with biopharma companies and developing its own internal drug pipeline. Their market focus spans collaborations with major pharmaceutical companies and research institutions.
Notable figures associated with PostEra include Aaron Morris. The company has raised $26 million from top investors and secured $1 billion in AI partnerships, including multi-year agreements with industry giants like Amgen, Pfizer, and the NIH. PostEra also spearheaded the world's largest open-science drug discovery initiative. These achievements underscore PostEra's significant impact on the biopharma industry, positioning it as a leader in AI-driven drug discovery.

Insitro
insitro.com

Numerion Labs
numerionlabs.ai

Pathos AI
pathos.com

Model Medicines
modelmedicines.com

1910
1910genetics.com

DeepCure
deepcure.ai

Elucidata
elucidata.io

Biosim

Owkin
owkin.com

Terray Therapeutics
terraytx.com

Zephyr AI
zephyrai.bio

Persist AI
persist-ai.com

Superluminal Medicines
superluminalrx.com

Cognaisent
cognaisent.com

Ordaos
ordaos.bio
Companies similar to PostEra include Insitro, Numerion Labs, Pathos AI and Model Medicines.
PostEra was founded in 2019.
PostEra's headquarters is located in Boston, MA, US.
As of May 18, 2022, PostEra has raised a total of $26.3M (USD).
PostEra has 34 employees as of Mar 29, 2024.